Related Experiment Video

Updated: Aug 19, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[Long-term application of warfarin or acenocumarol in patients with fibrillating arrhythmia: the effects compared]

E S Kropacheva, E P Panchenko, D M Ataullakhanova

    Klinicheskaia Meditsina
    |March 12, 2005
    PubMed

    Insights

    For patients with ciliary arrhythmia, warfarin and acenocoumarol show equal efficiency in preventing thromboembolic events. Long-term warfarin therapy offers a lower complication risk due to more stable anticoagulation.

    Area of Science:

    • Cardiology
    • Internal Medicine
    • Pharmacology

    Background:

    • Thromboembolic complications, including cerebral infarction and systemic embolism, pose significant risks for patients with ciliary arrhythmia.
    • Left atrial appendage thrombosis, often detected by transesophageal echocardiography, is a primary source of thromboembolism in these patients.
    • Effective primary and secondary prevention strategies for thromboembolic complications in ciliary arrhythmia remain a critical clinical challenge.

    Purpose of the Study:

    • To compare the efficacy and safety of warfarin versus acenocoumarol in patients with ciliary arrhythmia without valvular lesions.
    • To evaluate the long-term outcomes, including thromboembolic and hemorrhagic complications, of anticoagulation therapy.

    Main Methods:

    • Observational study analyzing patient data.
    • Treatment groups received either warfarin or acenocoumarol.
    • 12-month therapy monitoring for efficacy and complications.

    Main Results:

    • Both warfarin and acenocoumarol demonstrated comparable efficacy in preventing thromboembolic complications.
    • The frequency of hemorrhagic complications was similar between the two anticoagulant groups after 12 months.
    • Warfarin therapy resulted in a more stable level of anticoagulation, correlating with a reduced risk of complications during long-term use.

    Conclusions:

    • Warfarin and acenocoumarol are equally effective in managing thromboembolic risk in ciliary arrhythmia.
    • Long-term warfarin therapy may offer a safety advantage due to more consistent anticoagulation levels, potentially lowering complication rates.

    More Related Videos

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

    Published on: February 26, 2013

    Related Concept Videos

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...